VIDEO: World Conference on Lung Cancer offers ‘impactful treatment-related research’
Click Here to Manage Email Alerts
In this video, Andrew Ciupek, PhD, discusses findings from the Alliance trial, IMpower010 and NADIM-2.
The findings from all three studies, highlighted during the Presidential Symposium, were presented at the World Conference on Lung Cancer.
The Alliance trial investigated sublobar resection in patients with early-stage non-small cell lung cancer compared with the standard of care, lobectomy resection.
“One of the things I like about the conference is that it covers a wide range of the lung cancer care continuum and we saw a couple areas of impactful treatment-related research,” Ciupek, associate director of clinical research at GO2 Foundation for Lung Cancer, told Healio.
IMpower010 compared treatment with atezolizumab (Tecentriq, Genentech) with the standard of care in the early-stage setting, similar to the Alliance trial. NADIM-2, a phase 2 study, evaluated neoadjuvant chemotherapy among patients with resectable clinical stage IIIa non-small cell lung cancer.
References:
- Altorki NK, et al. Abstract PL0306. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
- Felip E, et al. Abstract PL03.09. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
- Provencio M, et al. Abstract PL03.12. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts